Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID
Authors' conclusion
Taken together, MTX treatment reduces vaccine-induced CD4 T cell activation, which correlates with lower antibody responses.
Study context
- Population
- Patients with IMID (rheumatoid arthritis (RA), PsA) on methotrexate (MTX) monotherapy, untreated RA and healthy controls receiving two SARS-CoV-2 mRNA vaccinations
- Comparison
- MTX monotherapy vs RA without immunosuppressive treatment and healthy controls, after two SARS-CoV-2 mRNA vaccinations
- RA without immunosuppressive treatmentn = 10
- Healthy controlsn = 29reference
- Outcome
- B and CD4 T cell SARS-CoV-2 vaccination responses
- Follow-up
- 7 days and 3-6 months after two vaccinations
Methodological detailshigh-dimensional flow cytometry, activation-induced marker assay, spike probes
- High-dimensional flow cytometry
- Activation-induced marker assay
- Spike probes
Main finding
As reported in the abstract
Vaccine responses 7 days after two SARS-CoV-2 vaccinations
- Total B and T cell counts similar between MTX-treated patients and controls
- Spike-specific B cell frequencies unaffected
- Frequency of antigen-specific CD4 T cells reduced in patients using MTX
- Antigen-specific CD4 T cell frequency correlated strongly with anti-RBD IgG antibodies
Original publication
Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID. RMD Open. Published 7 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →